Zai Lab (NASDAQ:ZLAB) Trading 11.7% Higher – Should You Buy?

Zai Lab Limited (NASDAQ:ZLAB)’s share price traded up 11.7% on Friday . The company traded as high as $35.00 and last traded at $34.62. 435,270 shares traded hands during trading, a decline of 36% from the average session volume of 677,179 shares. The stock had previously closed at $30.99.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald upgraded shares of Zai Lab to a “strong-buy” rating in a research note on Wednesday, February 5th.

Zai Lab Stock Up 8.7 %

The company has a 50-day moving average of $26.75 and a 200 day moving average of $25.11. The firm has a market capitalization of $3.69 billion, a PE ratio of -12.18 and a beta of 1.02.

Insider Transactions at Zai Lab

In other news, insider Rafael Amado sold 7,583 shares of the firm’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $26.28, for a total transaction of $199,281.24. Following the sale, the insider now owns 33,834 shares in the company, valued at approximately $889,157.52. This trade represents a 18.31 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 13.88% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. bought a new stake in Zai Lab during the fourth quarter worth about $29,000. Pictet Asset Management Holding SA purchased a new position in shares of Zai Lab during the 4th quarter valued at about $31,000. Barclays PLC lifted its position in Zai Lab by 337.6% in the 4th quarter. Barclays PLC now owns 3,702 shares of the company’s stock worth $97,000 after buying an additional 2,856 shares during the last quarter. US Bancorp DE boosted its stake in Zai Lab by 1,671.9% in the fourth quarter. US Bancorp DE now owns 5,865 shares of the company’s stock worth $154,000 after buying an additional 5,534 shares in the last quarter. Finally, Jasper Ridge Partners L.P. bought a new position in Zai Lab during the fourth quarter valued at approximately $210,000. Institutional investors own 41.65% of the company’s stock.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.